Skip to main content

Table 1 Characteristic of Patients with CTC detection

From: Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Characteristics Total No. patients (%) P
CTC HER2+ CTC HER2-
Overall 58 22 (37.9) 36 (62.1)  
Age (years)     
 Median 48.5 49.0 46.5 0.289
 Range 27–68 29–68 27–65
ER and/or PR     
 Positive 33 8 (24.2) 25 (75.8) 0.014
 Negative 25 14 (56.0) 11 (44.0)
No. of Metastasis     
 1 8 5 (62.5) 3 (37.5) 0.238
 ≥ 2 50 17 (34.0) 33 (66.0)
Metastatic sites     
 Visceral 44 16 (36.4) 28 (63.6) 0.663
 Non-visceral 14 6 (42.9) 8 (57.1)
DFS     
 ≤ 12 24 12 (50.0) 12 (50.0) 0.111
 > 12 34 10 (29.4) 24 (70.6)
Systemic therapy line     
 1 7 5 (71.4) 2 (28.6) 0.092
 ≥ 2 51 17 (33.3) 34 (66.7)
Treatment option     
 Trastuzumab + Chemo 43 19 (44.2) 24 (55.8) 0.096
 Lapatinib + Chemo 15 3 (20.0) 12 (80.0)